BerandaLCTX • NYSEAMERICAN
add
Lineage Cell Therapeutics Inc
$1,92
Setelah Jam Perdagangan Normal:(1,56%)-0,030
$1,89
Tutup: 27 Feb, 19.01.59 GMT-5 · USD · NYSEAMERICAN · Pernyataan Penyangkalan
Tutup sebelumnya
$1,96
Rentang hari
$1,89 - $1,97
Rentang tahun
$0,37 - $2,09
Kapitalisasi pasar
442,23Â jt USD
Volume Rata-Rata
1,12Â jt
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 3,68Â jt | -2,59% |
Biaya operasional | 7,28Â jt | -1,70% |
Penghasilan bersih | -29,78Â jt | -881,58% |
Margin laba bersih | -809,05 | -907,66% |
Penghasilan per saham | -0,13 | -550,00% |
EBITDA | -3,61Â jt | 2,46% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 40,49Â jt | 23,77% |
Total aset | 89,64Â jt | -7,20% |
Total liabilitas | 68,84Â jt | 116,49% |
Total ekuitas | 20,80 jt | — |
Saham yang beredar | 230,33 jt | — |
Harga terhadap nilai buku | 19,60 | — |
Tingkat pengembalian aset | -10,49% | — |
Tingkat pengembalian modal | -26,04% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Sep 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -29,78Â jt | -881,58% |
Kas dari operasi | -3,62Â jt | 37,52% |
Kas dari investasi | -12,00Â rb | -100,31% |
Kas dari pembiayaan | 1,83Â jt | 61.233,33% |
Perubahan kas bersih | -1,80Â jt | 3,54% |
Arus kas bebas | -2,61Â jt | -15,03% |
Tentang
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Didirikan
1990
Situs
Karyawan
74